Drugs / Thymosin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04268537 | Feb → Apr 2020 | COVID-19 | Southeast University, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymosin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04268537 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL412531 ↗ |
| Route | Subcutaneous | “Thymosin 1.6 mg sc qd, last for 5 days” NCT04268537 ↗ |